Pseudoprogression and Pseudoresponse in the Management of High-Grade Glioma: Optimal Decision Timing According to the Response Assessment of the Neuro-Oncology Working Group

Ji Hyun Chang, M.D.,1 Chae-Yong Kim, M.D.,2 Byung Se Choi, M.D.,3 Yu Jung Kim, M.D.,4 Jae Sung Kim, M.D.,1 In Ah Kim, M.D., Ph.D.1
Departments of Radiation Oncology,1 Neurosurgery,2 Radiology,3 Internal Medicine,4 Seoul National University Bundang Hospital, Seongnam, Korea

Objective: We evaluated pseudoprogression (PsPD) following radiation therapy combined with concurrent temozolomide (TMZ), and we assessed pseudoresponse following anti-angiogenic therapy for patients with recurrent disease using the Response Assessment of the Neuro-Oncology Working Group.

Methods: Patients who were pathologically confirmed as having high-grade glioma received radiotherapy with concurrent TMZ followed by adjuvant TMZ. Bevacizumab (Avastin) with CPT-11 were used as a salvage option for cases of radiologic progression. Magnetic resonance imaging (MRI) was routinely performed 1 month after concurrent radiochemotherapy (CRT) and every 3 months thereafter. For cases treated with the bevacizumab-containing regimen for progressive disease, MRI was performed every 2 months.

Results: Of 55 patients, 21 (38%) showed radiologic progression within 4 weeks after CRT. Of these patients, 16 (29%) showed progression at second post-CRT MRI (etPD) and five (9%) showed improvement (PsPD). Seven of thirty-four initially non-progressed patients showed progression at the second post-CRT MRI (ltPD). No difference in survival was observed between the etPD and ltPD groups ($p=0.595$). Five (50%) of ten patients showed a radiological response after salvage bevacizumab therapy. Four of those patients exhibited rapid progression immediately after discontinuation of the drug (drug holiday).

Conclusion: Twelve weeks following treatment could be the optimal timing to determine PsPD or true progression. MRI with gadolinium enhancement alone is not sufficient to characterize tumor response or growth. Clinical correlation with adequate follow-up duration and histopathologic validation may be helpful in discriminating PsPD from true progression.

Key Words: High-grade glioma · Concurrent radiochemotherapy · Pseudoprogression · Pseudoresponse.

INTRODUCTION

Pseudoprogression (PsPD) and pseudoresponse (PsR) following anticancer therapy are major areas of controversy in the management of high-grade glioma. In the era of temozolomide, discrimination of PsPD and true progression of high-grade glioma after concurrent radiochemotherapy (CRT) with conventional magnetic resonance imaging (MRI) are extremely challenging. Novel imaging modalities such as MR spectroscopy, positron emission tomography (PET), and perfusion MRI are showing promising results but have yet to be validated in prospective studies. We previously reported the significance of overexpression of p53 for predicting development of PsPD10. In addition to the method of interpretation for early radiologic deterioration, when to determine this is also a critical issue because it affects the clinician’s decision making regarding whether to switch to salvage therapy for recurrent disease or to continue planned adjuvant therapy. The timing of defining early progression varies from 4 weeks to 6 months1,4,16,21,24. As PsPD was termed “early necrosis” in early reports, many series determined PsPD at 4 weeks after treatment. Conversely, Wen et al.28 proposed new Response Assessment in Neuro-Oncology...
nine patients received 60 Gy in 30 fractions, and one patient
received 59.4 Gy in 33 fractions. The median time from surgery
to the initiation of CRT was 26 days (range of 11-77 days).
TMZ concomitant with postoperative RT was administered
at 75 mg/m² a day. For adjuvant TMZ, 150-200 mg/m² was ad-
ministered daily for 5 days, every 28 days.
In terms of salvage therapy following recurrence, the surgical
resection was performed for the patients who had a small pro-
gressive lesion involving non-eloquent area, and gamma knife
surgery was reserved for the cases with small lesions and medi-
cally inoperable condition. Bevacizumab with or without CPT-11
was considered as a primary option for salvage therapy in all
inoperable cases showing true progression. Bevacizumab was used
at a dose of 10 mg/kg. The patients who had previous episode of
intracranial hemorrhage or who were not able to afford beva-
cizumab received nimustine (ACNU)/cisplatin (CDDP) or pro-
carbazine, lomustine, and vincristine (PCV) chemotherapy, or
metronomic TMZ.

Assessment of response and statistical analysis
MRI with gadolinium enhancement and T2/FLAIR was per-
formed 1 month after CRT and every 3 months thereafter. When a
progressive finding was present, MRI was performed at
2-month intervals. Progression was defined as a more than 25%
increase in the sum of the products of perpendicular diameters
as in the Macdonald criteria, an increase in the non-enhancing
lesion in recurrent cancer with bevacizumab[15]. Each MRI scan
was thoroughly reviewed with a neuroradiologist.
EtPD and ltPD were defined as true progression found at first
and second post-treatment MRI with the exception of PsPD,
respectively. PsR was scored when progressive enhancement or
a non-enhancing T2-weighted lesion was shown right after re-
sponse to bevacizumab, or after discontinuation of the drug
due to toxicity. In some cases, cerebral blood flow (CBF), cere-
bral blood volume (CBV) values using perfusion MRI, and ap-
parent diffusion coefficient (ADC) maps were used to discrimi-
nate PsPD or PsR versus true progression. The Kaplan-Meier
method was used for the survival analysis to compare OS be-
tween etPD and ltPD.

RESULTS
Patient characteristics
Patient and tumor characteristics are shown in Table 1. Forty
(73%) patients were diagnosed with glioblastoma multiforme.
All patients were treated with RT combined with concurrent
and adjuvant TMZ after surgical resection or stereotactic biop-
sy. Four patients could not continue adjuvant TMZ due to poor
general condition.
Nine (24%) of thirty-seven patients with disease progression
during all treatment period and 1 case of PsPD were treated with
bevacizumab with or without CPT-11. Surgical resection, gam-
ma knife surgery, ACNU/CDDP, PCV chemotherapy, or metrono-
ic TMZ were also used as an option for the salvage therapy.
In 13 of 55 patients CBV, ADC, or PET were undertaken, and it was insufficient number to analyze the efficiency of the techniques. The exams only provided additional information and were not absolute means of diagnosis.

**Incidence of etPD, ltPD, and PsPD**

At the first follow-up after CRT, 21 patients (38%) showed radiologic progression. And at second post-CRT MRI, 16 (29%) of them persistently showed progression and considered as etPD. Five (9%) of those patients showed progression after the first MRI taken at post-treatment 4 weeks and showed improvement afterwards without specific salvage treatment with a decreasing or stable dose of dexamethasone. These groups of patients were finally categorized as PsPD. And at second post-CRT MRI, 7 showed new progression that was not seen in previous MRI (ltPD). The details of each category are shown in Table 2.

**Survival outcomes**

The follow-up time was defined as the period between surgery (including stereotactic biopsy) and the last follow-up day or death. The estimated median survival was 25.6 months (range of 3.3-89.7 months). The OS rates at 1 and 2 years were 84.8% and 59.2%, respectively. When divided into WHO grade III and IV gliomas, OS at 2 years were 71.4% and 53.3%, respectively ($p=0.125$).

As shown in Fig. 1, the OS of the etPD group vs. ltPD group was 57% vs. 86% at 1 year, and OSs were 30% and 51% at 2 years, respectively. No statistically significant difference was found between etPD and ltPD groups ($p=0.595$).

We also performed subgroup analysis in 33 patients having available data for O-6 methylguanine-DNA methyltransferase (MGMT) methylation status. Although there was no statistically significant OS difference between the patients with methylated MGMT and those with unmethylated MGMT ($p=0.178$), it showed trend toward better survival with MGMT methylation (Fig. 2).

In multivariate analysis using covariates (recursive partitioning analysis, WHO grade, p53 status, MGMT methylation status and extent of resection), none of the factors including etPD and ltPD was related to OS.

The median survivals of treatment with or without bevacizumab, were 10 and 6 months, respectively ($p=0.835$).

**Pseudoresponse**

Although 5 (50%) of 10 patients showed a radiological response following salvage treatment with bevacizumab, the response was durable in one case and the stable state persisted for 11 months. The others experienced rapid progression after improvement (Table 3). For one case, the MRI scan showed decreased high T2 signal intensity 1 month after bevacizumab and CPT-11, the lesion showed progression at the subsequent follow-up, and we considered this case to be PsPD. For three other cases, radiologic improvements were shown within 3 months and bevacizumab was continued until thromboembolic events in two cases and cerebral infarction in one case. All showed rapid regrowth of the tumor immediately after discontinuation of bevacizumab on MRI (Fig. 3).

**DISCUSSION**

The primary goal of this study was to evaluate the survival difference between etPD and ltPD. Thus, we could not identify a statistically significant survival difference between the two groups, indicating that it would be safe to continue planned adjuvant TMZ rather than treatment for recurrence when radiologic progression appears in the first post-treatment MRI. This unique treatment strategy dealing with radiologic progression for high-grade glioma comes from the absence of a diagnostic modality providing high accuracy and resemblance between

| Table 1. Patient and tumor characteristics |
|-------------------------------------------|
| **Characteristics**                       | **No. (%)** |
| **Patient**                               |             |
| Age (yrs)                                 | 57         |
| Median                                    | 24-84      |
| Gender                                    |             |
| Male                                       | 27 (49)    |
| Female                                     | 28 (51)    |
| Initial KPS                               |             |
| 100                                        | 12 (22)    |
| 90                                         | 26 (47)    |
| 80                                         | 8 (15)     |
| 70                                         | 6 (11)     |
| 60                                         | 3 (5)      |
| RTOG RPA class                            |             |
| <5                                         | 26 (47)    |
| ≥5                                         | 29 (53)    |
| **Tumor**                                 |             |
| Histology                                 |             |
| Glioblastoma                              | 40 (73)    |
| Anaplastic astrocytoma                    | 11 (20)    |
| Anaplastic oligodendroglioma              | 4 (7)      |
| Surgical removal                          |             |
| GTR                                        | 16 (29)    |
| NTR                                        | 3 (5)      |
| STR                                        | 22 (40)    |
| Stereotactic biopsy                       | 14 (26)    |
| MGMT methylation status                   |             |
| Positive                                  | 12 (22)    |
| Negative                                  | 21 (38)    |
| Not available                             | 22 (40)    |

KPS: Karnofsky performance status, RTOG: Radiation Therapy Oncology Group, RPA: recursive partitioning analysis, GTR: gross total resection, NTR: near total resection, STR: subtotal resection, MGMT: O-6 methylguanine-DNA methyltransferase
Table 2. Summary of the clinical courses of patients with PsPD, etPD, and ltPD

| Patient No. | Progression on image* (wks) | Treatment after recurrence (on image) | MGMT methylation | Overall survival (months) | Status |
|-------------|-----------------------------|--------------------------------------|------------------|--------------------------|--------|
| PsPD        |                             |                                      |                  |                          |        |
| 1           | 4                           | BVZ†                                 | +                | 51.5                     | SD     |
| 2           | 4                           | Adjuvant TMZ                         | 3 months         | N/A                      | 18.1   | DOD    |
| 3           | 4                           | Adjuvant TMZ                         | 2 months         | N/A                      | 27.0   | SD     |
| 4           | 4                           | Adjuvant TMZ                         | 3 months         | N/A                      | 37.9   | SD     |
| 5           | 4                           | Adjuvant TMZ                         | SD → decreased after 6 months | +          | 13.9   | SD     |
| etPD        |                             |                                      |                  |                          |        |
| 1           | 4                           | Adjuvant TMZ                         | Ventricular seeding | N/A        | 10.8   | DOD    |
| 2           | 4                           | Adjuvant TMZ                         | In-field         | N/A                      | 13.3   | DOD    |
| 3           | 4                           | Adjuvant TMZ → ACNU+CDDP             | In-field         | -                        | 7.5    | DOD    |
| 4           | 4                           | CPT-11                               | In-field         | +                        | 15.3   | DOD    |
| 5           | 2                           | Adjuvant TMZ → ACNU+CDDP             | In-field         | N/A                      | 6.5    | DOD    |
| 6           | 3                           | Adjuvant TMZ → metronomic TMZ        | In-field         | N/A                      | 24.2   | SD     |
| 7           | 4                           | Adjuvant TMZ                         | In-field/ventricular seeding | N/A      | 5.0    | DOD    |
| 8           | 5                           | Adjuvant TMZ → tumor removal          | CSF seeding      | N/A                      | 23.2   | DOD    |
| 9           | 5                           | Adjuvant TMZ                         | Out-field        | +                        | 30.4   | SD     |
| 10          | 5                           | Adjuvant TMZ                         | Clinical deterioration (SD on MRI) | N/A    | 16.3   | PD     |
| 11          | 3                           | Adjuvant TMZ                         | In-field         | N/A                      | 3.4    | DOD    |
| 12          | 5                           | Adjuvant TMZ                         | In-field/ventricular seeding | -         | 4.3    | PD     |
| 13          | 5                           | None‡                                | In-field         | N/A                      | 8.2    | PD     |
| 14          | 4                           | Adjuvant TMZ → palliative RT         | CSF seeding      | -                        | 4.9    | DOD    |
| 15          | 4                           | Adjuvant TMZ → GKS                   | In-field         | N/A                      | 25.1   | PD     |
| 16          | 4*                          | Adjuvant TMZ                         | In-field/ventricular seeding | -         | 3.2    | PD     |
| ltPD        |                             |                                      |                  |                          |        |
| 1           | 8                           | Adjuvant TMZ → ACNU+CDDP             | In-field         | -                        | 11.1   | DOD    |
| 2           | 16                          | Adjuvant TMZ → metronomic TMZ        | In-field         | +                        | 25.7   | DOD    |
| 3           | 16                          | Craniotomy                           | In-field         | -                        | 13.1   | DOD    |
| 4           | 18                          | Adjuvant TMZ → ACNU+CDDP             | In-field         | N/A                      | 12.7   | PD     |
| 5           | 18                          | Adjuvant TMZ → BVZ+CPT-11            | In-field         | -                        | 13     | SD     |
| 6           | 12                          | Adjuvant TMZ → GKS                   | In-/out-field    | -                        | 15.6   | SD     |
| 7           | 14                          | Adjuvant TMZ                         | In-field         | +                        | 15.7   | PD     |

*From the day end of CRT, †Bevacizumab was administered after tumor decreased and showed pseudoresponse, ‡Could not continue adjuvant therapy due to status epilepticus. PsPD : pseudoprogression, etPD : early true progression, ltPD : late true progression, MGMT : O-6 methylguanine-DNA methyltransferase, BVZ : bevacizumab, TMZ : temozolomide, N/A : not applicable, SD : stable disease, PD : progressive disease, DOD : died of disease, ACNU : nimustine, CDDP : cisplatin, RT : radiotherapy, CSF : cerebrospinal fluid, GKS : gamma knife surgery, CRT : concurrent radiochemotherapy.

Fig. 1. Kaplan-Meier curve showing overall survival of the etPD and ltPD groups. etPD : early true progression, ltPD : late true progression.

Fig. 2. Kaplan-Meier curve showing overall survival of the MGMT methylation and unmethylation groups (available data, p=0.178). MGMT : 0-6 methylguanine-DNA methyltransferase.
in-field recurrence and treatment response as PsPD or radiation necrosis. The mechanism of PsPD which is exclusive phenomenon in high-grade glioma, is not clarified, but might be related to the nature of tumor itself. Blood tumor barrier of glioma has high expression of P-glycoprotein, a 170-kDa drug efflux pump protein, which is the main component of blood brain barrier (BBB) and inhibits penetration\(^2\). Generally, glioblastoma has compromised barrier that gadolinium can penetrate and shows enhancement. But if the BBB is not altered the lesion presents as nonenhancing tumor. BBB breakage after RT has been well documented but the mechanism is unclear. In vitro study showed that RT induces early transient increase in paracellular permeability while maintaining the tight junction of capillary endothelial cells\(^2\). An experimental study revealed that higher exposures of TMZ in brain tumor can also attribute to breakdown of the BBB\(^9\). Increased permeability of blood tumor barrier caused by RT and TMZ would result in contrast enhancement due to leakage, which presents as PsPD. PsPD therefore should be defined retrospectively because it mimics tumor progression.

RANO criteria were suggested to overcome the limitation of Macdonald criteria and drew considerable attentions. Although it provides innovative assessment in the treatment of malignant glioma, yet several limitations were pointed out as discriminating true or false lesions in non-enhancing lesions, too simple tumor size measurement, and not reflecting any of new imaging techniques\(^9\). Despite current criteria as Macdonald or RANO, purely objective judgement of treatment response only with imaging is difficult in practice. Increased CBV/CBF and a decreased ADC value do not imply progressive disease at all times, however, the decisions are made from these novel imaging modalities for most of the confusing cases. Also, interpreting non-enhanced lesions has raised another dilemma in clinical practices. Latest imaging techniques as dynamic susceptibility contrast MRI perfusion, diffusion-weighted MRI, MRI/PET scans using biomarker, and thallium single photon emission CT are introduced but no comparison under prospective studies have been performed\(^9\). Thus, disparity sometimes in clinical judgment between oncologists and radiologists makes further treatment planning more complex and often needs to be discussed by a multidisciplinary tumor board. Nevertheless, without pathologic confirmation, the possibility of misdiagnosis always exists. For example, one patient who was considered to show PsPD in our last study was confirmed to show true progression by surgery. In this case, CBV was not increased and the tumor demonstrated stabilization after 4 weeks at the second post-treatment MRI, which could be considered to be PsPD. Recently, Vogelbaum et al.\(^9\) suggested that retrospective assessments of serial images to distinguish PsPD form true progression and when the finding is ambiguous, the response should be called indeterminate even with RANO criteria. This shows despite the latest techniques and reorganization of the criteria they do not guarantee even with RANO criteria. This shows despite the latest techniques and reorganization of the criteria they do not guarantee more reliable diagnosis or appropriate further treatment plan therefore validation should be needed. Retrospective comparative analysis among various criteria has been performed placing emphasis on the nonenhancing tumor\(^9\). The major component that we adopted from RANO was the timing of defining PsPD varied\(^9\). In the review of Sanghera et al.\(^1\), timing of defining PsPD varied from 2 weeks to 6 months among 8 studies. Considering that most of the decisions are made at 4 weeks or 6 months in prospective analysis among various criteria has been performed placing emphasis on the nonenhancing tumor. Also in Canadian recommendations PsPD cannot be diagnosed until 12 weeks after the end of RT unless new lesion shows out-of-field\(^9\). In the review of Sanghera et al.\(^1\), timing of defining PsPD varied from 2 weeks to 6 months among 8 studies. Considering that most of the decisions are made at 4 weeks or 6 months in performed studies, it should be confirmed that observation until 12 weeks is not related to decreased OS as in the present study. As our data showed no difference between etPD and ltPD, confirmation after serial observations would be reasonable rather

| Patient No. | No. of cycles | Time to response* | Drug holiday | MGMT methylation status | Cause of drug holiday | Time to regrowth (from drug off) |
|------------|---------------|-------------------|--------------|--------------------------|----------------------|---------------------------------|
| 1          | 13            | 3 months          | +            | +                        | Thromboembolism       | 3 months                        |
| 2\(^1\)    | 24            | 1 month           | +            | -                        | Cerebral infarction   | 2 months                        |
| 3          | 3             | 2 months          | +            | -                        | Thromboembolism       | 2 months                        |
| 4          | 4             | 1 month           | -            | +                        | -                    | 1 month                         |

*Checked by magnetic resonance imaging, \(^1\)Same patient with PsPD : pseudoprogression patient 1 in Table 2. MGMT : O-6 methylguanine-DNA methyltransferase
than deciding early from a little information.

Correlation between MGMT methylation and PsPD, and association with improved OS has been reported by Brandes et al.[5]. In our study, the survival graph comparing MGMT methylated/unmethylated group showed difference but not statistically significant. It might be due to a small size of the available data.

Another crucial debate concerning PsPD is its potential presentation with PsR. As PsPD may reflect increased BBB permeability, administration of bevacizumab under misdiagnosis of true progression normalizes a leaky vasculature and therefore may show a “response”[30]. It is highly persuasive but only a hypothesis and needs further examination in the future study. In the present study, we observed one case of partial response from bevacizumab. The regression of in-field recurrence occurred 1 month after administration of the drug, and remained stable disease for 11 months. However, as we had impression of both possibilities, true progression vs. treatment related change, we still cannot rule out late PsPD in this case. Others have also reported 2 cases of bevacizumab treatment of symptomatic PsPD[30]. Counting such cases as the treatment effect may result in a falsely high response rate to an anti-angiogenic agent. As we cannot perform pathologic confirmation in every suspected recurrence, PsPD and PsR should not be considered separately.

Regarding PsR, conflicting views exist concerning interpretation of the response to bevacizumab in recurrent high-grade glioma. As mentioned earlier, a strikingly high response rate and progression-free survival (PFS) does not result in increased OS; thus, doubt exists regarding whether bevacizumab has an anti-tumor effect. In a pooled analysis by Norden et al.[30], a statistically significant increase was found in PFS of patients receiving bevacizumab; however, OS demonstrated no statistically significant difference. In the same context, an argument exists for using PFS as a surrogate for survival[12,13].

Bevacizumab causes adverse effects such as intracranial hemorrhage, thromboembolic events, and proteinuria[3]. In a phase II study of bevacizumab and CPT-11 in recurrent malignant glioma, 4 of 32 (13%) patients had a thromboembolic event and two of them died of toxicity/neurologic deterioration[27]. We observed three (30%) thromboembolic toxicities that caused discontinuation of the drug. Those cases were all bevacizumab responsive and underwent re-progression shortly after cessation. One possible advantage of bevacizumab is considered to be reduction of corticosteroid use[31], but paradoxically it can cause dependency on bevacizumab, which is one of the most expensive drugs. Additionally, bevacizumab can cause VEGF-independent mechanisms of progression in the heavily treated patients[30]. Furthermore, as glioblastoma is known to be associated with a high risk of thromboembolism, anti-coagulation would be needed to prevent severe complication[30]. However, not every patient planning to be administered bevacizumab can receive prophylaxis, and thus a positive effect for survival may be counterbalanced. This life-threatening toxicity cannot be overlooked, and costs and benefits must be considered.

One of the limitations of the current study is showing high OS than other reported data, and this may be due to censored data, as 9 of the patients were unavailable for follow-up[27]. When recurrence was suspected, salvage treatment varied among patients because until now there is no standard chemotherapy regimen in the management of high-grade glioma.

Although small-sized and retrospective in nature, the present study suggests methodology and evidence for the safety of postponed treatment of recurrent high-grade glioma until 12 weeks after termination of CRT and shows clinical features of PsR, raising a question about the true effect of bevacizumab.

CONCLUSION

Initiating a further treatment plan after 12 weeks as recommended by RANO does not lead to loss of overall survival. Additionally, in recurrent high-grade glioma, bevacizumab must be administered with caution in consideration of PsPD and PsR. However, MRI with gadolinium enhancement alone is not sufficient to characterize tumor response or growth. In addition to clinical correlation with adequate duration of follow-up and histopathologic validation, further studies regarding additional physiologic imaging modalities are required for accurate evaluation of tumor response.

• Acknowledgements

This work was supported by the grants (#2012-004867, 2013 RIAIA 2074531) from National Research Foundation, Korean Ministry of Future Creative, Science to Kim IA.

References

1. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26: 2192-2197, 2008
2. Caroline I, Rosenthal MA: Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis? J Clin Neurosci 19: 633-637, 2012
3. Chamberlain MC: Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5: 117-129, 2011
4. Chakiss C, Neyns B, Michotte A, De Ridder M, Everaert H: Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 72: 423-428, 2009
5. Easaw JC, Mason WP, Perry J, Laperrère N, Eisenstat DD, Del Maestro R, et al.: Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18: e126-e136, 2011
6. Faquette W, Amourette C, Dehouck MP, Diserbo M: Radiation-induced blood-brain barrier damages: an in vitro study. Brain Res 1433: 114-126, 2012
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiiff D, Abrey LE, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009
8. Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, González-Aguilar A, Houllier C, et al.: Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Pseudoprogression and Pseudoresponse in the Management of High-Grade Glioma

JH Chang, et al.

Neuro Oncol 14 : 667-673, 2012
9. Joo JD, Chang JH, Kim JH, Hong YK, Kim YH, Kim CY : Temozolomide during and after radiotherapy for newly diagnosed glioblastomas : a prospective multicenter study of Korean patients. J Korean Neurosurg Soc 52 : 92-97, 2012
10. Kang HC, Kim CY, Han JH, Choe GY, Kim JH, Kim JH, et al. : Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy : potential role of p53. J Neurooncol 102 : 157-162, 2011
11. Kreil TN, Kim I, Moore K, Duic P, Royce C, Stroud I, et al. : Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 : 740-745, 2009
12. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. : Progression-free survival : an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10 : 162-170, 2008
13. Laymon CM, Oborski MJ, Lee VK, Davis DK, Wiener EC, Lieberman FS, et al. : Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme : correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. Magn Reson Imaging 30 : 1268-1278, 2012
14. Lutz K, Radbruch A, Wiestler O, Bäumer P, Wick W, Bendzus M : Neuroradiological response criteria for high-grade gliomas. Clin Neuroradiol 21 : 199-205, 2011
15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-1280, 1990
16. Mangla R, Singh G, Ziegelitz D, Milano MT, Korones DN, Zhong J, et al. : Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256 : 575-584, 2010
17. Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, et al. : Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases. Neuro Oncol 15 : 650-655, 2013
18. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, et al. : An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92 : 149-155, 2009
19. Pan E, Tsai JS, Mitchell SB : Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res 29 : 4309-4313, 2009
20. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, et al. : A new model for prediction of drug distribution in tumor and normal tissues : pharmacokinetics of temozolomide in glioma patients. Cancer Res 69 : 120-127, 2009
21. Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M, et al. : Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37 : 36-42, 2010
22. Sanghera P, Rampling R, Haylock B, Jefferies S, McBain C, Rees JH, et al. : The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clin Oncol (R Coll Radiol) 24 : 216-227, 2012
23. Scherrmann JM : Expression and function of multidrug resistance transporters at the blood-brain barriers. Expert Opin Drug Metab Toxicol 1 : 233-246, 2005
24. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. : Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoradiation with temozolomide. Cancer 113 : 405-410, 2008
25. Thompson EM, Frenkel EP, Neuweit EA : The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76 : 87-93, 2011
26. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, et al. : Application of novel response/progression measures for surgically delivered therapies for gliomas : Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 70 : 234-243; discussion 243-244, 2012
27. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, et al. : Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 : 1253-1259, 2007
28. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. : Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 28 : 1963-1972, 2010
29. Young RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z, et al. : MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging 37 : 41-49, 2013